The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
N. Yamamoto
No relevant relationships to disclose
N. Katakami
No relevant relationships to disclose
S. Atagi
No relevant relationships to disclose
T. Hida
No relevant relationships to disclose
K. Goto
Honoraria - Chugai Pharma
T. Horai
No relevant relationships to disclose
A. Inoue
No relevant relationships to disclose
Y. Ichinose
No relevant relationships to disclose
K. Kobayashi
No relevant relationships to disclose
K. Takeda
No relevant relationships to disclose
K. Kiura
Honoraria - Chugai Pharma
Research Funding - Meiji Seika Kaisha
H. Saka
No relevant relationships to disclose
T. Tamura
No relevant relationships to disclose
I. Okamoto
Honoraria - Chugai Pharma; Lilly; Taiho Pharmaceutical
N. Nogami
No relevant relationships to disclose
R. Morinaga
No relevant relationships to disclose
K. Nishio
No relevant relationships to disclose
Y. Seki
Employment or Leadership Position - Boehringer Ingelheim
R. M. Lorence
Employment or Leadership Position - Boehringer Ingelheim
M. Shahidi
Employment or Leadership Position - Boehringer Ingelheim